PROJECT VACCINE AND THE EPSTEIN CONNECTION

Key Takeaways

• Gates Foundation bought BioNTech shares for $55 million in 2019
• Epstein linked DARPA research to Gates vaccine strategy
• DARPA’s ADEPT project funded Moderna and Curevac mRNA work
• BioNTech’s COVID‑19 vaccine derived from NIH‑Moderna design
• Foundation sold shares at $300 each, earning $260 million profit

Summary

In 2019 the Bill & Melinda Gates Foundation invested $55 million to acquire a minority stake in BioNTech, positioning itself to profit from the company’s mRNA COVID‑19 vaccine. Internal documents and Epstein‑related files reveal that Jeffrey Epstein, JP Morgan executives, and DARPA helped shape a pandemic‑preparedness framework that funneled public‑health funding toward private biotech firms. The Gates Foundation sold 86% of its BioNTech shares in 2021 at roughly $300 each, netting about $260 million in profit after a $55 million purchase. The article argues that these coordinated actions created a lucrative “vaccine cartel” that benefitted a handful of investors during the COVID‑19 crisis.

Pulse Analysis

The partnership between the Bill & Melinda Gates Foundation and biotech firms predates the pandemic, rooted in the 2010 Decade of the Vaccine initiative. By leveraging DARPA’s early mRNA research—particularly the ADEPT and later P3 projects—the foundation helped shape a pipeline that funneled public‑sector grants into private companies like Moderna, Curevac, and BioNTech. This alignment of government research, private capital, and philanthropic funding created a structural advantage for investors poised to profit once a global health emergency emerged.

When the SARS‑CoV‑2 outbreak appeared, the groundwork laid by DARPA and the Gates Foundation accelerated vaccine development. BioNTech’s mRNA candidate, built on the NIH‑Moderna prefusion‑stabilised spike design, received rapid regulatory pathways in the EU and the U.S. The Gates Foundation’s minority stake meant it stood to gain directly from any successful rollout. By mid‑2021, the foundation liquidated most of its holdings at roughly $300 per share, turning a $55 million outlay into a $260 million gain after modest taxes. This profit narrative underscores how pandemic preparedness can double as a financial strategy for well‑connected entities.

The broader implication is a potential erosion of public trust in health institutions. When philanthropic bodies, intelligence agencies, and private financiers converge on vaccine development, the line between public good and profit blurs. Policymakers and investors must now grapple with heightened scrutiny over conflict‑of‑interest disclosures, ensuring that future pandemic responses prioritize equitable access over shareholder returns.